170 related articles for article (PubMed ID: 21515406)
1. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics.
Kojima C; Turkbey B; Ogawa M; Bernardo M; Regino CA; Bryant LH; Choyke PL; Kono K; Kobayashi H
Nanomedicine; 2011 Dec; 7(6):1001-8. PubMed ID: 21515406
[TBL] [Abstract][Full Text] [Related]
2. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and in vivo pharmacokinetics.
Lim J; Turkbey B; Bernardo M; Bryant LH; Garzoni M; Pavan GM; Nakajima T; Choyke PL; Simanek EE; Kobayashi H
Bioconjug Chem; 2012 Nov; 23(11):2291-9. PubMed ID: 23035964
[TBL] [Abstract][Full Text] [Related]
4. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent.
Han L; Li J; Huang S; Huang R; Liu S; Hu X; Yi P; Shan D; Wang X; Lei H; Jiang C
Biomaterials; 2011 Apr; 32(11):2989-98. PubMed ID: 21277017
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biodistribution, and imaging of PEGylated-acetylated polyamidoamine dendrimers.
Liu J; Liu J; Chu L; Tong L; Gao H; Yang C; Wang D; Shi L; Kong D; Li Z
J Nanosci Nanotechnol; 2014 May; 14(5):3305-12. PubMed ID: 24734545
[TBL] [Abstract][Full Text] [Related]
6. Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents.
Laus S; Sour A; Ruloff R; Tóth E; Merbach AE
Chemistry; 2005 May; 11(10):3064-76. PubMed ID: 15776490
[TBL] [Abstract][Full Text] [Related]
7. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents.
Kobayashi H; Kawamoto S; Saga T; Sato N; Hiraga A; Ishimori T; Konishi J; Togashi K; Brechbiel MW
Magn Reson Med; 2001 Oct; 46(4):781-8. PubMed ID: 11590655
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
9. PEGylated polyamidoamine dendrimers with bis-aryl hydrazone linkages for enhanced gene delivery.
Yuan Q; Yeudall WA; Yang H
Biomacromolecules; 2010 Aug; 11(8):1940-7. PubMed ID: 20593893
[TBL] [Abstract][Full Text] [Related]
10.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
11. PAMAM dendrimers conjugated with an uncharged gadolinium(III) chelate with a fast water exchange: the influence of chelate charge on rotational dynamics.
Polásek M; Hermann P; Peters JA; Geraldes CF; Lukes I
Bioconjug Chem; 2009 Nov; 20(11):2142-53. PubMed ID: 19883075
[TBL] [Abstract][Full Text] [Related]
12. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores.
Kobayashi H; Kawamoto S; Jo SK; Bryant HL; Brechbiel MW; Star RA
Bioconjug Chem; 2003; 14(2):388-94. PubMed ID: 12643749
[TBL] [Abstract][Full Text] [Related]
13. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography.
Peng C; Zheng L; Chen Q; Shen M; Guo R; Wang H; Cao X; Zhang G; Shi X
Biomaterials; 2012 Feb; 33(4):1107-19. PubMed ID: 22061490
[TBL] [Abstract][Full Text] [Related]
14. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
[TBL] [Abstract][Full Text] [Related]
15. Poly(amidoamine) dendrimer based MRI contrast agents exhibiting enhanced relaxivities derived via metal preligation techniques.
Nwe K; Bryant LH; Brechbiel MW
Bioconjug Chem; 2010 Jun; 21(6):1014-7. PubMed ID: 20462240
[TBL] [Abstract][Full Text] [Related]
16. New nanosized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules.
Ogawa M; Regino CA; Marcelino B; Williams M; Kosaka N; Bryant LH; Choyke PL; Kobayashi H
Bioconjug Chem; 2010 May; 21(5):955-60. PubMed ID: 20235572
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers.
Jászberényi Z; Moriggi L; Schmidt P; Weidensteiner C; Kneuer R; Merbach AE; Helm L; Tóth E
J Biol Inorg Chem; 2007 Mar; 12(3):406-20. PubMed ID: 17216229
[TBL] [Abstract][Full Text] [Related]
18. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Kusamori K; Sakane T; Yamamoto A
J Control Release; 2017 Sep; 262():10-17. PubMed ID: 28710004
[TBL] [Abstract][Full Text] [Related]
19. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents.
Tan M; Ye Z; Jeong EK; Wu X; Parker DL; Lu ZR
Bioconjug Chem; 2011 May; 22(5):931-7. PubMed ID: 21473650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
